Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 2—February 2026

Research Letter

Monkeypox Virus Antibodies in Healthy Persons after Vaccination with MVA-BN, United Kingdom

Victoria H. Sheridan, Craig W. Duffy, Jake Dunning, Lance Turtle, Julian A. Hiscox, Krishanthi S. SubramaniamComments to Author , and on behalf of the ISARIC4C Investigators1
Author affiliation: University of Liverpool, Liverpool, UK (V.H. Sheridan, C.W. Duffy, L. Turtle, J.A. Hiscox, K.S. Subramaniam); University of Oxford, Oxford, UK (J. Dunning); Royal Liverpool University Hospital, Liverpool (L. Turtle)

Main Article

Figure

Titer results in study of monkeypox virus antibodies in healthy persons after MVA-BN vaccination, United Kingdom. PRNT50 titers for participants vaccinated with 2 doses of MVA-BN vaccine demonstrated neutralizing antibody responses to monkeypox virus clade Ib and clade IIb. A) Assessment of the contribution of complement on neutralization illustrating the different conditions tested: purple, HI; red, HI and GPS; blue, non-HI. Mann Whitney U test used to determine p values. B) PRNT50 values for clades Ib and IIb. Wilcoxon matched pairs signed rank test used to determine p values. Blue indicates negative controls; yellow, vaccine recipients; red, participants with underlying conditions. Each data point represents the geometric mean titer of 2 experimental replicates; horizontal black lines indicate medians. PRNT50 values were determined using Probit regression. GPS, guinea pig serum; HI, heat-inactivation; MVA-BN, modified vaccinia Ankara–Bavarian Nordic vaccine; NS, not significant; PRNT50, log of 50% endpoint plaque reduction neutralization test.

Figure. Titer results in study of monkeypox virus antibodies in healthy persons after MVA-BN vaccination, United Kingdom. PRNT50 titers for participants vaccinated with 2 doses of MVA-BN vaccine demonstrated neutralizing antibody responses to monkeypox virus clade Ib and clade IIb. A) Assessment of the contribution of complement on neutralization illustrating the different conditions tested: purple, HI; red, HI and GPS; blue, non-HI. Mann Whitney U test used to determine p values. B) PRNT50 values for clades Ib and IIb. Wilcoxon matched pairs signed rank test used to determine p values. Blue indicates negative controls; yellow, vaccine recipients; red, participants with underlying conditions. Each data point represents the geometric mean titer of 2 experimental replicates; horizontal black lines indicate medians. PRNT50 values were determined using Probit regression. GPS, guinea pig serum; HI, heat-inactivation; MVA-BN, modified vaccinia Ankara–Bavarian Nordic vaccine; NS, not significant; PRNT50, log of 50% endpoint plaque reduction neutralization test.

Main Article

1More information about the group is at the end of this article.

Page created: January 22, 2026
Page updated: February 20, 2026
Page reviewed: February 20, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external